Remed Co

Remed Co Capital Expenditures

The Capital Expenditures (CapEx) of Remed Co (302550.KQ) as of Nov 19, 2026 is -868.76 M KRW. In the previous year, Capital Expenditures (CapEx) was -608.80 M KRW — a change of 42.70% (lower).

Capital Expenditures

-868.76 MKRW

YoY

42.70%

Last updated:

Capital Expenditures (CapEx) of Remed Co is 2025 -868.76 M KRW. Capital Expenditures (CapEx) of Remed Co was 2024 -608.80 M KRW. It decreases by 42.70% lower compared to the previous year.

The Remed Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-5.01 B KRW
Jan 1, 2019
-2.01 B KRW
Jan 1, 2020
-679.62 M KRW
Jan 1, 2021
-4.88 B KRW
Jan 1, 2022
-4.77 B KRW
Jan 1, 2023
-893.97 M KRW
Jan 1, 2024
-608.80 M KRW
Jan 1, 2025
-868.76 M KRW
The Remed Co Capital Expenditures history
YEARCapital ExpendituresYoY
-868.76 MKRW+42.70%
-608.80 MKRW-31.90%
-893.97 MKRW-81.26%
-4.77 BKRW-2.24%
-4.88 BKRW+617.94%
-679.62 MKRW-66.19%
-2.01 BKRW-59.85%
-5.01 BKRW+551.05%
-768.89 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Capital Expenditures (CapEx) of Remed Co is -868.76 M KRW in 2025.

Capital Expenditures (CapEx) of Remed Co changed from -608.80 M KRW to -868.76 M KRW, representing a 42.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Remed Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Remed Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Remed Co

All Key Metrics — Remed Co